ABL Bio Inc. (298380)

Overview

ABL Bio Inc. is a pioneering biotech research company dedicated to advancing the field of medicine through innovative drug development. Based in Seongnam, South Korea, ABL Bio Inc. specializes in creating therapeutic drugs designed to combat immuno-oncology and neurodegenerative diseases. With a focus on addressing some of the most challenging conditions facing patients today, ABL Bio Inc. is committed to harnessing the power of biotechnology to achieve breakthroughs in treatment options and improve patient outcomes.

Products and Services

• ABL001

  ABL001 is a groundbreaking cancer immunotherapy treatment developed by ABL Bio Inc. This innovative approach harnesses the body's immune system to target and eliminate cancer cells, offering a promising alternative to traditional cancer treatments. ABL001 represents a significant stride in immuno-oncology, aiming to provide patients with more effective and less invasive treatment options.

• ADC (Antibody-Drug Conjugates)

  ABL Bio Inc. is at the forefront of ADC technology, developing targeted therapy that delivers cytotoxic drugs to cancer cells with precision. This method minimizes damage to healthy cells while maximizing the destruction of cancerous tissue, thereby offering a more efficient and safer treatment for various types of cancer.

• ABL301

  As part of its commitment to addressing neurodegenerative diseases, ABL Bio Inc. is developing ABL301, a novel therapeutic drug aimed at treating conditions such as Parkinson's disease. ABL301 focuses on targeting and mitigating the pathological proteins responsible for neurodegeneration, offering hope for a disease-modifying treatment that could significantly improve the quality of life for patients suffering from these debilitating conditions.